Cue Biopharma Inc
CUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$121.39M
Close$
$-0.76
104.6% downside
Current Fair Value
104.6% downsideOvervalued by 104.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $121.39 Million |
|---|---|
| Enterprise Value | $107.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.4 |
| Beta | 2.63 |
| Outstanding Shares | 6,340,844 |
Return
| Return on Equity | -7104.24% |
|---|---|
| Return on Assets | -534.43% |
| Return on Invested Capital | -1043.34% |
Valuation & Multiples
| P/E Ratio | -0.62 |
|---|---|
| PEG | -0.04 |
| Price to Sales | 3.34 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.84 |
| Enterprise Value to EBIT | -1.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 1.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-2.24
Average shareholder expectationRevenue Estimate
$1.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2865▲ 28.65% |
|---|---|
| Total Calls | 34,906▲ Infinity% |
| Total Puts | 10,000▼ 21.26% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 34.44%▲ 19.59% |
|---|---|
| Total Invested | $52.25M▲ 954.75% |
| Investors Holding | 52▼ 3.00% |
ESG Score
No data
About Cue Biopharma Inc
CEO: Daniel Passeri